Please login to the form below
Pharmaceutical Market Europe (PME)
PME is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to the issues that keep industry leaders awake at night.
From the latest developments in cancer treatments and the strategies behind them to new marketing and commercialisation models and the regulations that underpin the fabric of the sector – PME's got it covered.
PME is a trusted source for decision makers and influencers in pharma and healthcare who, through the practical and accessible content, have the knowledge to tackle whatever comes their way.
AZ secures capacity for one billion coronavirus vaccine doses
Initial agreement to supply 400 million doses of Oxford University’s vaccine
EMA starts review of MorphoSys’ tafasitamab for lymphoma
Drug could challenge Novartis and Gilead’s CAR-T therapies if approved
Gilead, Galapagos dip on mixed ulcerative colitis data
Drug may not work well enough to displace rivals
Roche makes protein degradation play with $135m Vividion deal
Exclusive deal with Vividion includes potential for “multibillion dollar future payments”
Articles
-
Taking the ‘free’ out of ‘freelance’ and bringing it in-houseLet's face it, the freelance life offers numerous benefits
-
Emerging use cases of blockchain in healthcare and the life sciences
By Charles Wright
-
Managing virtual teamsWith coronavirus leading to mass home working, how do we get the best from our now virtual teams while supporting their health and well-being
-
Risks, reforms and rewards: the evolving Russian healthcare marketWhile reforms introduced in the past two decades have brought stability and sought to address some of the structure issues, problems remain
-
Biopharma and orphan drugsRare disease drug approvals are improving, thanks to regulatory support
Pharmaceutical Market Europe - May 2020
Pharmaceutical Market Europe (PME) magazine is also available on the iPhone/iPad as a free app
Editor - Iona Everson
Have your say...
Subscribe
FDA gives Roche’s Tecentriq green light for first-line NSCLC
Company enters lucrative and competitive market dominated by Merck/MSD’s rival Keytruda
'Nothing about us without us'
Why patient engagement is essential throughout the entire product life cycle
Taking the ‘free’ out of ‘freelance’ and bringing it in-house
Let's face it, the freelance life offers numerous benefits
COVID-19 Updates and Daily News
Featured jobs
- Imperial College London to lead major coronavirus home testing programme
- Regeneron says antibody for COVID-19 could be ready this year
- Moderna’s coronavirus vaccine hits first objectives
- Roche says antibody test for COVID-19 should be ready in May
- Novartis claims EU approval for SMA gene therapy Zolgensma
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
- Why are new medicinal products denied reimbursement in France?
- Lucid Group are shortlisted in three categories for Communiqué 2020
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
- Gilead, Galapagos dip on mixed ulcerative colitis data
PMHub
Havas Life Medicom
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...
Latest intelligence
- DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
- This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
- Why are new medicinal products denied reimbursement in France?
- Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
Quick links
Infographics
